RESISTANCE MODIFICATION BY PSC-833, A NOVEL NONIMMUNOSUPPRESSIVE CYCLOSPORINE-A

被引：196

作者：

TWENTYMAN, PR

BLEEHEN, NM

机构：

[1] MRC Clinical Oncology and Radiotherapeutics Unit, Cambridge, CB2 2QH, Hills Road

来源：

EUROPEAN JOURNAL OF CANCER | 1991年 / 27卷 / 12期

关键词：

D O I：

10.1016/0277-5379(91)90435-G

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A novel non-immunosuppressive cyclosporin A, PSC-833, has been tested for its ability to circumvent resistance to doxorubicin, vincristine and colchicine in human and murine multidrug resistantant (MDR) cell lines. This compound is shown to be a highly potent resistance modifier, being 7-10-fold more potent than the parent compound, cyclosporin A, whilst approximately equal to cyclosporin A in the growth inhibitory effects of compound alone. Reversal of the P-glycoprotein-associated MDR drug accumulation defect is a major component of resistance reversal for PSC-833, as it is for cyclosporin A.

引用

页码：1639 / 1642

页数：4